News

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served as Chairman since 2020, will continue to serve as a member of the Board of Directors.

“We are delighted to welcome Dr. Williams as Chairman of our Board of Directors,” said David Marek, Chief Executive Officer of ReAlta. “His exceptional track record in building successful biopharmaceutical companies and expertise in drug development will be invaluable as ReAlta advances its clinical programs.”

“I would like to welcome Rusty to ReAlta at this exciting time in the company’s evolution,” said Buzz Heidt, member of ReAlta’s Board of Directors. “Rusty brings a wealth of leadership experience and insight to ReAlta, and I am eager to work with him as our incoming Board Chairman.”

“On behalf of the entire Board,” said Mr. Marek, “I wish to extend our sincerest gratitude to Buzz Heidt for over four years of Board service to ReAlta. Buzz’s collaborative partnership in the boardroom and strong leadership has positioned ReAlta for long-term success and Rusty and I look forward to his continued contributions as a Board member.”

“ReAlta is taking an innovative approach to address inflammation – the key driver of diseases across a wide spectrum of therapeutic areas. The unique ability of ReAlta’s dual-targeting EPICC peptides to address the earliest stages of the inflammatory cascade holds promise for treating inflammatory diseases successfully in ways existing therapies have been unable to,” said Dr. Williams. “I look forward to working closely with the Board Directors and management team to help realize the full potential of ReAlta’s technology to benefit patients with severe inflammatory diseases who currently have limited therapeutic options.”

Learn more here. 

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin